Helix BioPharma Corp. HBP.TO
Nov 3, 2026, 3:07 PM EST
- YTD
- -61.18%
- 1 year
- -56.40%
- Market cap
- 70.27M
- EPS (ttm)
- -0.04
- Shares out
- 49.02M
- Forward P/E
- -8.82
- YTD return
- -61.18%
- 1-year return
- -56.40%
- Volume
- 4.60K
- Avg volume
- 8.05K
- Open
- 0.98
- Previous close
- 1.02
- Day's range
- 0.90 – 0.98
- 52-week range
- 0.82 – 2.60
- Beta
- -0.84
2Y +0.1400 (+18.42%)
Key statistics
- Enterprise value
- 45.49M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -2.75M
- Total cash
- 1.08M
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.01%
- 50-day average
- 0.9002
- 200-day average
- 1.06
Next earnings
Consensus EPS estimate 0.00.
About Helix BioPharma Corp.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- helixbiopharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on HBP.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Antas (Jacek Marek) | Director of Issuer | Acquisition or disposition under a prospectus exemption | Nov 2, 2022 | 3,191,600 |
| Leszczynski (Jerzy Alfred) | Director of Issuer | Acquisition or disposition under a prospectus exemption | Nov 2, 2022 | 1,683,344 |
| Maciejewski (Krzysztof (Christopher)) | Director of Issuer | Opening Balance-Initial SEDI Report | Apr 17, 2022 | 680,036 |
| Wilczewski (Jerzy) | 10% Security Holder of Issuer | Acquisition or disposition under a prospectus exemption | Apr 21, 2022 | 31,167,153 |